A 66-year-old patient with end-stage renal failure lived for 271 days with a genetically modified pig kidney before successfully receiving a human donor organ, according to findings published in The Lancet. The milestone case, detailed by researchers at Massachusetts General Hospital, highlights the expanding clinical potential of xenotransplantation to serve as an interim bridge for patients stranded on long organ waiting lists.
Tim Andrews received the experimental kidney on January 25, 2025, after doctors determined he faced a high risk of mortality while waiting for a compatible human organ. The procedure allowed Andrews to forego dialysis for more than eight months, restoring routine physical activities before microvascular inflammation necessitated the organ's removal in October 2025.
Genetic Engineering and the EGEN-2784 Design
The transplanted organ originated from a Yucatan miniature pig and underwent a complex array of 69 distinct gene edits engineered by biotechnology firm eGenesis, founded by Harvard University researcher George Church. Marketed in clinical data under the designation EGEN-2784, the modifications were structured across three primary biological fronts designed to prevent immediate rejection and pathogen transmission.
First, the engineering protocol removed three specific pig antigen genes responsible for triggering hyperacute rejection in human recipients. Second, researchers inserted seven human genes intended to enhance overall immune system compatibility. Finally, the design inactivated 59 copies of porcine endogenous retroviruses, known as PERVs, to eliminate the theoretical risk of human viral infection. According to the medical team, these foundational edits represent a sophisticated approach to overcoming immunological barriers between species.
Clinical Progression and Complications
Following the January 2025 surgery, Andrews experienced early complications when a biopsy conducted 14 days post-transplant confirmed T cell-mediated rejection. Medical staff successfully resolved this immune response through targeted intervention, allowing the organ to function stably for roughly half a year, during which Andrews maintained normal physical mobility.
However, microvascular inflammation eventually developed inside the kidney, progressing into thrombotic microangiopathy by the autumn of 2025. This complication forced the medical team to remove the pig kidney on October 23, 2025, after which Andrews resumed temporary dialysis treatment while awaiting a human organ match.
Successful Transition to Human Transplant
Despite the months of exposure to animal tissue, subsequent clinical evaluations confirmed that Andrews had developed no new antibodies targeting human tissue, nor were any porcine-derived pathogens detected in his system. These clinical findings demonstrated that the prolonged xenotransplantation period did not impede a subsequent human organ procedure.
On January 13, 2026, roughly three months after the removal of the experimental graft, surgeons performed a successful human donor kidney transplant. Hospital records indicate that the operation proceeded without complication, and no significant adverse effects have emerged during the subsequent six months of medical monitoring.
Broader Clinical Implications and Waiting List Crisis
Medical investigators emphasized that xenotransplantation addresses a severe shortage within global healthcare systems. More than 100,000 individuals remain on the United States organ donor waiting list, where many patients suffer physical deterioration while awaiting compatible human kidneys.
Lead author Dr. Leonardo V. Riella, associate professor of nephrology at Massachusetts General Hospital, underscored the critical role of patient participation. "The organ shortage is the greatest crisis we have right now in transplantation," Dr. Riella said, praising the recipient's courage. "Our vision is that xenotransplantation could help address this gap—initially as a bridge to get patients off dialysis while they wait for a human donor kidney, and potentially, as we establish long-term safety and durability, as a destination therapy in its own right."
Expanding Trials and International Horizons
While Andrews' 271-day duration surpassed previous benchmarks—including a 130-day case involving an Alabama patient—the record has already been eclipsed. Another female patient who received an eGenesis pig kidney at Massachusetts General Hospital on November 22, 2025, has maintained renal function without dialysis for 285 days as of September 2026.
Commercial developers plan to expand these evaluations, with eGenesis targeting a formal clinical trial for up to 33 kidney failure patients aged 50 to 77 in 2027, pending regulatory review by the U.S. Food and Drug Administration. Meanwhile, international interest is growing, as Japan's administrative roadmap incorporates xenotransplantation, with corporate trials projected to launch by 2028 through collaborations between domestic universities and medical centers.
